We compared the effect of GPX3 on platinum-based chemotherapy sensitivity in several types of cancer cells (Figure 9B), and the results showed that shGPX3 resulted in increased sensitivity to platinum-based chemotherapy in breast cancer, ovarian cancer, colorectal cancer, and gastric cancer. Here, GPX3 is linked to ovarian carcinoma.